Document Detail


Effect of maintenance therapy with low-dose peginterferon for recurrent hepatitis C after living donor liver transplantation.
MedLine Citation:
PMID:  21129128     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
Summary.  Approximately 30% of patients who have recurrent hepatitis C after liver transplantation achieve sustained virological response (SVR) by taking a combination therapy of pegylated interferon and ribavirin. For the remaining non-SVR patients, an effective management treatment has not yet been established. In this study, efficacy of long-term peginterferon maintenance therapy for non-SVR patients was evaluated. Forty patients who had previously received the combination therapy for hepatitis C after living donor liver transplantation were classified into one of the following three groups: the SVR group (n = 11); the non-SVR-IFN group (n = 17), which received low-dose peginterferon maintenance therapy for non-SVR patients; and the non-SVR-Withdrawal group (n = 12), which discontinued the interferon treatment. We then compared histological changes among these three groups after 2 or more years follow-up. Activity grade of liver histology improved or remained stable in patients in the SVR and non-SVR-IFN groups, but deteriorated in half of the patients in the non-SVR-Withdrawal group. Fibrosis improved or remained stable in 10 of 11 SVR patients and in 13 of 17 non-SVR-IFN patients, but deteriorated in all non-SVR-Withdrawal patients. Mean changes in fibrosis stage between pretreatment and final liver biopsy were -0.18, +0.06 and +2.2 in the SVR, non-SVR-IFN and non-SVR-Withdrawal groups, respectively. Fibrosis stage deteriorated to F3 or F4 significantly more rapidly in the non-SVR-Withdrawal group than in the other two groups. In conclusion, continuing long-term maintenance therapy with peginterferon prevented histological progression of hepatitis C in patients who had undergone living donor liver transplantation.
Authors:
Y Ueda; H Marusawa; T Kaido; Y Ogura; F Oike; A Mori; K Ogawa; A Yoshizawa; E Hatano; A Miyagawa-Hayashino; H Haga; H Egawa; Y Takada; S Uemoto; T Chiba
Related Documents :
21393338 - Prevalence of long-term oral glucocorticoid prescriptions in the uk over the past 20 ye...
8497618 - Varicoceles: postoperative prevalence--a prospective study with color doppler us.
7658538 - The nesbit operation for peyronie's disease: 16-year experience.
21121798 - Does the gamma knife dose rate affect outcomes in radiosurgery for trigeminal neuralgia?
12716588 - Off-pump coronary artery bypass surgery may produce a hypercoagulable patient.
24282908 - Morphology of the oviduct of commercial egg-laying hens supplemented with organic miner...
Publication Detail:
Type:  Journal Article     Date:  2010-12-03
Journal Detail:
Title:  Journal of viral hepatitis     Volume:  19     ISSN:  1365-2893     ISO Abbreviation:  J. Viral Hepat.     Publication Date:  2012 Jan 
Date Detail:
Created Date:  2011-12-22     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9435672     Medline TA:  J Viral Hepat     Country:  England    
Other Details:
Languages:  eng     Pagination:  32-8     Citation Subset:  IM    
Copyright Information:
© 2010 Blackwell Publishing Ltd.
Affiliation:
Department of Gastroenterology and Hepatology Department of Surgery Department of Diagnostic Pathology, Graduate School of Medicine, Kyoto University, Shogoin, Sakyo-ku, Kyoto, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Hepatitis A outbreaks: the effect of a mass vaccination programme.
Next Document:  Impact of liver steatosis on the correlation between liver stiffness and fibrosis measured by transi...